Intelligence · Clinical pipeline
Phase II Pipeline Programs
Proof-of-concept and dose-finding clinical programs in Phase II development.
Quick answer
NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.
Top sponsors
- Chinese Academy of 432 programs
- BRIGHT MINDS BIOSCIENCES 393 programs
- First People's Hospital 375 programs
- United Therapeutics Europe 336 programs
- Takeda 335 programs
- Anaxis Pharma 223 programs
- George Institute for 187 programs
- Regeneron UK 176 programs
- Teva Pharma 126 programs
- Novartis India 121 programs
- Telethon Foundation 119 programs
- Disc Medicine 106 programs
Pipeline programs
-
Tirzepatide
BRIGHT MINDS BIOSCIENCES INC.
Cannabis Use Disorder
1 trial -
Tirzepatide
BRIGHT MINDS BIOSCIENCES INC.
Smoking Cessation
1 trial -
Tirzepatide
Regeneron UK Limited
Obesity
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Cancer
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Biliary Tract Tumor
1 trial -
Tislelizumab
Takeda
Minimal Residual Disease
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Thyroid Cancer
1 trial -
Tislelizumab
Hospital Authority, Hong Kong
Pancreatic Neoplasms
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Advanced Unresectable Gastric Adenocarcinoma
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Colorectal Cancer
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Gastroesophageal Adenocarcinoma
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinoma
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Resectable Esophageal Squamous Cell Carcinoma
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HNSCC
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
RECTAL NEOPLASMS
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Bladder Urothelial Carcinoma
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
HER2-positive or Mutated Advanced Colorectal Cancer
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Pancreatic Neoplasms
1 trial -
Tislelizumab
BeiGene
Cervical Cancer
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
Tislelizumab (BGB-A317)
BEONE MEDICINES AUS PTY LTD
MSI-H/dMMR Solid Tumors
1 trial -
Tislelizumab combined with chemoradiotherapy
The First People's Hospital of Lianyungang
ESCC
1 trial -
Tislelizumab combined with chemotherapy
The First People's Hospital of Lianyungang
Rectal Cancer
1 trial -
Tizanidine (sublingual or oral)
Teva Pharma GmbH
Muscle Spasticity
1 trial -
TmBU conditioning Regimen
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Tobacco free snuff
BRIGHT MINDS BIOSCIENCES INC.
Tobacco Use Disorder
1 trial -
Tocilizumab
United Therapeutics Europe Ltd
Pulmonary Arterial Hypertension
1 trial -
Tocilizumab
Hospital Authority, Hong Kong
Adamantinomatous Craniopharyngioma
1 trial -
Tocilizumab Injectable Product
Tang-Du Hospital
Myasthenia Gravis, Generalized
1 trial -
Tofacitinib
Peking University People's Hospital
Primary Sjögren's Syndrome
1 trial -
TolDec
The George Institute
Multiple sclerosis
1 trial -
Tolcapone
BRIGHT MINDS BIOSCIENCES INC.
Tobacco Use Disorder
1 trial -
Tolecizumab (PCSK9 Inhibitor)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colon Adenocarcinoma
1 trial -
Tolinapant, Tolinapant
Taiho Pharma Netherlands B.V.
Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy
1 trial -
Tongjiang granule
Universal Integrated
Gastroesophageal Reflux
1 trial -
Topical Minocycline Foam FXFM244
VYNE Therapeutics
Acne Vulgaris
1 trial -
Topical Minocycline Foam FXFM244
VYNE Therapeutics
Rosacea
1 trial -
Topical Minocycline Foam FXFM244
VYNE Therapeutics
Impetigo
1 trial -
Topical Powder
Dermata Therapeutics
Acne Rosacea
1 trial -
Topical Rose Bengal, 0.005%
PROVECTUS BIOPHARMACEUTICALS, INC.
Psoriasis
1 trial -
Topical endoxifen
ATOSSA THERAPEUTICS, INC.
Mammographic Breast Density
1 trial -
Topical roflumilast 0.3% foam
Arcutis Biotherapeutics
Hidradenitis Suppurativa
1 trial -
Topiramate
BRIGHT MINDS BIOSCIENCES INC.
Cannabis Abuse
1 trial -
Topiramate
BRIGHT MINDS BIOSCIENCES INC.
Cocaine-Related Disorders
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Neoadjuvant Therapy
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Locally Advanced Colon Cancer
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial
Frequently asked questions
How many Phase II pipeline programs are in the directory?
7,238 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.